Li Xin Z Wang

20100077135, Mar 25, 2010

Jul 9, 2009

12/499859

Rong Li - San Diego CA, US
Yuefeng Jin - San Diego CA, US
Li Wang - San Diego CA, US

VIA TELECOM, INC. - San Diego CA

G06F 12/02
G06F 12/00

711103, 711E12001, 711E12008

A wear leveling method for a non-volatile memory is provided. The non-volatile memory includes a plurality of data blocks, each corresponding to a time value. The data blocks are arranged according to a sequence of the time values corresponding thereto. The arranged blocks form a key table. An erase operation is determined whether to be executed for the data blocks. When the erase operation is executed for the data blocks, the corresponding data block is erased according to a sequence of the time values of the data blocks in the key table.

20220275373, Sep 1, 2022

May 18, 2022

17/664032

- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US

C12N 15/113
A61K 9/127
A61K 31/713
A61K 31/7105

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

20210381056, Dec 9, 2021

Feb 12, 2021

17/175577

- Pleasanton CA, US
Vijay Kumar Sreenivasa Gopalan - San Diego CA, US
Li Wang - Pleasanton CA, US
Arundhati Shamoni Maheshwari - Oakland CA, US
Jasper Staab - Honolulu HI, US

C12Q 1/6886
G16B 40/00
G16B 15/00
G16B 5/20

Systems and methods for visualizing patterns in discrete attribute value datasets are provided. A dataset comprises a discrete attribute value for each gene in a plurality of genes, for each cell in a plurality of cells. The dataset further comprises ATAC counts for each ATAC peak in a plurality of peaks, for each of the cells. Cells are assigned cluster groups in a first plurality of cluster groups based on a first clustering of discrete attribute values for the genes across the cells. Cell are also assigned cluster groups in a second plurality of cluster groups based on a second clustering of ATAC fragment count values for the ATAC peaks across the cells. A projection of the cells uses one of the first or second cluster group assignments. There is indicated, for each cell within the projection, membership in the other of the first or second cluster group assignments.

20200157540, May 21, 2020

Nov 15, 2019

16/685283

- Osaka, JP
Jean-Pierre Clamme - San Diego CA, US
Li Wang - San Diego CA, US
Roger C. Adami - Carlsbad CA, US
Wenbin Ying - Oceanside CA, US

C12N 15/113
A61P 35/00
A61K 31/712
A61K 31/7125
A61K 47/28
A61K 47/24
A61K 9/14
A61K 9/19
A61K 9/16

This invention provides formulations for use in distributing RNAi molecules targeted to a human GST-π for treating a malignant tumor in a subject. The formulation can include nanoparticles composed of an ionizable lipid, a DSPE lipid, and additional lipids. A drug product can be made by lyophilization of the formulation. This invention further provides methods for ameliorating or treating a malignant tumor by administering a therapeutically effective amount of a formulation containing the RNAi agents.

20190367926, Dec 5, 2019

Aug 14, 2019

16/540973

- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US

C12N 15/113
A61K 9/127
A61K 31/713

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

20180358233, Dec 13, 2018

Jun 1, 2018

15/995173

- Tokyo, JP
Li Wang - Hillsboro OR, US
Andrew Nolan - Albany NY, US
Christopher Talone - Albany NY, US
Shyam Sridhar - Albany NY, US
Alok Ranjan - Austin TX, US
Hiroto Ohtake - Hillsboro OR, US

H01L 21/311
H01L 21/3065
H01L 21/3213

A method of etching is described. The method providing a substrate having a first material composed of silicon-containing organic material and a second material that is different from the first material, forming a chemical mixture by plasma-excitation of a process gas containing SFand an optional inert gas, controlling a processing pressure at or above 100 mtorr, and exposing the first material on the substrate to the chemical mixture to selectively etch the first material relative to the second material.

20180197730, Jul 12, 2018

Feb 23, 2017

15/440604

- Tokyo, JP
Li Wang - Portland OR, US
Andrew Nolan - Albany NY, US
Hiroto Ohtake - Hillsboro OR, US
Sergey Voronin - Delmar NY, US
Alok Ranjan - Tomiya-shi, JP

H01L 21/027
H01L 21/3065
H01L 21/306
H01L 21/033

Methods and systems for selective silicon anti-reflective coating (SiARC) removal are described. An embodiment of a method includes providing a substrate in a process chamber, the substrate comprising: a resist layer, a SiARC layer, a pattern transfer layer, and an underlying layer. Such a method may also include performing a pattern transfer process configured to remove the resist layer and create a structure on the substrate, the structure comprising portions of the SiARC layer and the pattern transfer layer. The method may additionally include performing a modification process on the SiARC layer of the structure, the modification converting the SiARC layer into a porous SiARC layer. Further, the method may include performing a removal process of the porous SiARC layer of the structure, wherein the modification and removal processes of the SiARC layer are configured to meet target integration objectives.

20180002702, Jan 4, 2018

Jun 28, 2017

15/636528

- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US

C12N 15/113
A61K 9/127
A61K 31/713

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.